Ramai D, Ofosu A, Solanki V, et al. - Using the Surveillance, Epidemiology, and End Results Registry, researchers tried to determine the incidence rate, the impact of multimodal therapy, as well as survival outcomes of rectal cancer in patients under 45 years of age. They analyzed 10,375 patients with young-onset rectal cancer, 54.7% were male. Between 2000 and 2016, the estimated overall age-adjusted incidence of rectal cancer was 1.24 per 100,000 per year. Rectal cancer rose by ∼2.29% during the 16-year study span. For rectal cancer, 1- and 5-year cause-specific survival of 93% and 72%, respectively, was obtained. Across all cancer stages, improved survival was achieved with surgery. Findings demonstrated increasing incidence of regional and distant rectal cancer in young patients. A crucial prognostic indicator of survival is patient age, and younger patients with localized and regional disease did not seem to experience improved survival when treated with chemotherapy.